Rakshak R, Bhatt S, Sharma S, Agharkar R, Bodakhe S, Srivastava R
Nanotheranostics. 2024; 8(3):330-343.
PMID: 38577323
PMC: 10988212.
DOI: 10.7150/ntno.93206.
Monterroso B, Margolin W, Boersma A, Rivas G, Poolman B, Zorrilla S
Chem Rev. 2024; 124(4):1899-1949.
PMID: 38331392
PMC: 10906006.
DOI: 10.1021/acs.chemrev.3c00622.
Alhashimi R, Ahmed T, Alghanem L, Pagare P, Huang B, Ghatge M
Pharmaceutics. 2023; 15(11).
PMID: 38004527
PMC: 10675597.
DOI: 10.3390/pharmaceutics15112547.
Karimi M, Bahadoram M, Mafakher L, Rastegar M
Hematol Transfus Cell Ther. 2023; 46(4):387-392.
PMID: 37652804
PMC: 11451392.
DOI: 10.1016/j.htct.2023.06.007.
Donkor A, Pagare P, Mughram M, Safo M
Front Mol Biosci. 2023; 10:1136970.
PMID: 37293554
PMC: 10244664.
DOI: 10.3389/fmolb.2023.1136970.
Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review.
Bhalla N, Bhargav A, Yadav S, Singh A
Front Med (Lausanne). 2023; 10:1036939.
PMID: 36910492
PMC: 9995916.
DOI: 10.3389/fmed.2023.1036939.
Design of an adaptive randomized clinical trial of intravenous citrulline for sickle cell pain crisis in the emergency department.
Majumdar S, McKinley K, Chamberlain J, Thomas B, Margulies S, Nickel R
Contemp Clin Trials Commun. 2023; 32:101077.
PMID: 36698745
PMC: 9868327.
DOI: 10.1016/j.conctc.2023.101077.
Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.
Huang B, Ghatge M, Donkor A, Musayev F, Deshpande T, Al-Awadh M
Molecules. 2022; 27(20).
PMID: 36296435
PMC: 9610770.
DOI: 10.3390/molecules27206835.
Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease.
Alhashimi R, Ghatge M, Donkor A, Deshpande T, Anabaraonye N, Alramadhani D
Biomolecules. 2022; 12(5).
PMID: 35625623
PMC: 9138457.
DOI: 10.3390/biom12050696.
Ionophore-mediated swelling of erythrocytes as a therapeutic mechanism in sickle cell disease.
Geisness A, Azul M, Williams D, Szafraniec H, De Souza D, Higgins J
Haematologica. 2021; 107(6):1438-1447.
PMID: 34706495
PMC: 9152977.
DOI: 10.3324/haematol.2021.278666.
The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications.
Wang Q, Zennadi R
Antioxidants (Basel). 2021; 10(10).
PMID: 34679742
PMC: 8533084.
DOI: 10.3390/antiox10101608.
Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.
Pagare P, Rastegar A, Abdulmalik O, Omar A, Zhang Y, Fleischman A
Expert Opin Ther Pat. 2021; 32(2):115-130.
PMID: 34657559
PMC: 8881396.
DOI: 10.1080/13543776.2022.1994945.
Pathologically stiff erythrocytes impede contraction of blood clots.
Tutwiler V, Litvinov R, Protopopova A, Nagaswami C, Villa C, Woods E
J Thromb Haemost. 2021; 19(8):1990-2001.
PMID: 34233380
PMC: 10066851.
DOI: 10.1111/jth.15407.
Sickle cell vaso-occlusion: The dialectic between red cells and white cells.
Conran N, Embury S
Exp Biol Med (Maywood). 2021; 246(12):1458-1472.
PMID: 33794696
PMC: 8243211.
DOI: 10.1177/15353702211005392.
VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
Abdulmalik O, Pagare P, Huang B, Xu G, Ghatge M, Xu X
Sci Rep. 2020; 10(1):20277.
PMID: 33219275
PMC: 7679387.
DOI: 10.1038/s41598-020-77171-2.
Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents.
Pagare P, Ghatge M, Chen Q, Musayev F, Venitz J, Abdulmalik O
J Med Chem. 2020; 63(23):14724-14739.
PMID: 33205981
PMC: 7869023.
DOI: 10.1021/acs.jmedchem.0c01287.
The multifaceted role of ischemia/reperfusion in sickle cell anemia.
Hebbel R, Belcher J, Vercellotti G
J Clin Invest. 2020; 130(3):1062-1072.
PMID: 32118586
PMC: 7269579.
DOI: 10.1172/JCI133639.
Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.
Olubiyi O, Olagunju M, Strodel B
Molecules. 2019; 24(24).
PMID: 31842406
PMC: 6943517.
DOI: 10.3390/molecules24244551.
MEK1/2 as a Therapeutic Target in Sickle Cell Disease.
Zennadi R
Int J Blood Res Disord. 2019; 6.
PMID: 31709379
PMC: 6839713.
DOI: 10.23937/2469-5696/1410038.
Valsartan impedes epinephrine-induced ICAM-4 activation on normal, sickle cell trait and sickle cell disease red blood cells.
Zhang J, Jones S, Lykotrafitis G, Andemariam B
PLoS One. 2019; 14(5):e0216467.
PMID: 31083675
PMC: 6513067.
DOI: 10.1371/journal.pone.0216467.